| アブストラクト | PURPOSE: Dipeptidyl peptidase-4 inhibitor (DPP-4-Is), a kind of drug used for the treatment of diabetes, is considered to prevent the degradation of substance P that suppresses the occurrence of dysphagia. On the other hand, DPP-4 inhibitors are also known to act on the immune system. In this study, we used a spontaneous reporting system to evaluate the signals for dysphagia and aspiration pneumonia with DPP-4-Is. METHODS: We calculated reporting odds ratio (ROR) and information coefficients (IC) as disproportionality analysis to evaluate DPP-4-Is induced dysphagia and aspiration pneumonia using the Japanese Adverse Drug Event Report (JADER) database. RESULTS: For DPP-4-Is as a class, no signals were detected for dysphagia, but the signal for aspiration pneumonia was detected at ROR 1.67 (95% confidence interval [95% CI]: 1.20 to 2.34) and IC 0.70 (95% CI: 0.21 to 1.19). For aspiration pneumonia, trelagliptin was the only drug among the DPP-4-Is for which both ROR and IC signals were detected (ROR 9.99, 95% CI: 4.10 to 24.36; IC: 1.98, 95% CI: 0.78 to 3.18). ROR signals, but not IC signals, were detected for linagliptin (ROR 2.66, 95% CI: 1.19 to 5.94; IC: 1.09, 95% CI: - 0.004 to 2.19) and sitagliptin (ROR 1.84, 95% CI: 1.04 to 3.25; IC: 0.78, 95% CI: - 0.03 to 1.58). CONCLUSION: Since DPP-4 inhibitors prevent the degradation of substance P involved in swallowing reflex, DPP-4 inhibitors were expected to prevent dysphagia and aspiration pneumonia. However, this study revealed that DPP-4 inhibitors strongly were associated with onset rather than preventing aspiration pneumonia. This result suggests that DPP-4 inhibitors may affect the immune function associated with the development of aspiration pneumonia. Furthermore, there is a possibility that the amount of DPP-4-Is used clinically cannot increase the amount of substance P in sufficient quantity to prevent aspiration pneumonia. |
|---|
| ジャーナル名 | European journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2019/12/12 |
|---|
| 投稿者 | Noguchi, Yoshihiro; Esaki, Hiroki; Murayama, Azusa; Sugioka, Mayuko; Koyama, Aisa; Tachi, Tomoya; Teramachi, Hitomi |
|---|
| 組織名 | Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.;noguchiy@gifu-pu.ac.jp.;Department of Pharmacy, Ichinomiya Municipal Hospital, Ichinomiya, Aichi, Japan.;teramachih@gifu-pu.ac.jp.;Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University,;Gifu, Japan. teramachih@gifu-pu.ac.jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31822955/ |
|---|
